A Phase 2 interventional study of PH-797804 and Placebo in Osteoarthritis, sponsored by Pfizer. Completed at 26 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2014-08-22.
Sponsored by Pfizer · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies in Osteoarthritis, Knee by Pfizer — 2 open to participants now, 2 under way, 2 of them phase 3. Osteoarthritis, Knee · Pfizer.
Among the 17 studies in Osteoarthritis, Knee by Pfizer, this one is the 11th largest by enrollment, is one of 2 that started in 2010, is one of 8 in phase 2, and was the 8th registered.
3,297 studies on the registry are indexed under Osteoarthritis, Knee; 623 are open to participants now.
Browse Osteoarthritis, Knee studies →2 of the 17 studies in Osteoarthritis, Knee by Pfizer are open now, in 2 countries. Recruiting first, the newest first:
Pfizer · Sites in United States
Ages 18+
Pfizer · Sites in United States, Canada
Ages 18+
By country, each count listing its studies:
Of the 384 Osteoarthritis, Knee studies recruiting now, 178 (46%) set no upper age limit and 113 (29%) stop at 75 or younger; 19 take children under 18; 39 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 2 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 172 is above the median of 68 across 2,719 interventional studies indexed under Osteoarthritis, Knee.
Median enrollment 200 across the 17 interventional studies. Of the 14 that completed or were terminated, 8 (57%) have results posted.
This tab as a report to print or save as PDF → With an account.
Pfizer is the lead sponsor of 3,338 studies on the registry; 147 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 393 (65%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 17 studies in Osteoarthritis, Knee by Pfizer, from their registry updates:
This tab as a report to print or save as PDF → With an account.
PH-797804 is a potent inhibitor of inflammatory mediators that have a potential role in pain signalling following nerve injury and inflammation. Blocking such mediators may potentially have a therapeutic benefit by reducing pain.
3,297 studies on the registry are indexed under Osteoarthritis, Knee; 623 are open to participants now.
This study's enrollment of 172 is above the median of 68 across 2,719 interventional studies indexed under Osteoarthritis, Knee.
Browse Osteoarthritis, Knee studies →Pfizer is the lead sponsor of 3,338 studies on the registry; 147 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 393 (65%) have results posted.
Compared within Osteoarthritis, Knee, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Osteoarthritis. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: PH-797804 · Drug: Placebo
Drug: Placebo · Drug: PH-797804
Drug: Naproxen · Drug: Naproxen + PH-797804
Drug: Naproxen + PH-797804 · Drug: Naproxen
Tablet, 6 mg once daily for 2 weeks
Tablet, 0 mg once daily for 2 weeks
Tablet, 0 mg once daily for 2 weeks
Tablet, 6 mg once daily for 2 weeks
Tablet, 500 mg twice daily for 2 weeks
Drug pages: NaproxenStudies of NaproxenNaproxen pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · PH 797804Studies of PH 797804PH 797804 pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
Tablet, 500 mg twice daily for 2 weeks and Tablet, 6 mg once daily for 2 weeks
Drug pages: NaproxenStudies of NaproxenNaproxen pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · PH 797804Studies of PH 797804PH 797804 pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
Tablet, 500 mg twice daily for 2 weeks and Tablet, 6 mg once daily for 2 weeks
Tablet, 500 mg twice daily for 2 weeks
Western Ontario & McMaster Osteoarthritis Index Pain Score
Time frame: 2 weeks
Western Ontario & McMaster Osteoarthritis Index Stiffness Score
Time frame: 2 weeks
Western Ontario & McMaster Osteoarthritis Index Physical Function Score
Time frame: 2 weeks
Western Ontario & McMaster Osteoarthritis Index Total Score
Time frame: 2 weeks
Daily Pain Rating Scale
Time frame: 2 weeks
The record gives a start of May 2010, a primary completion of Feb 2011 and a completion of Mar 2011. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: PH 797804 · Naproxen